Detailed explanation of the role, efficacy and clinical application scope of Eslicarbazepine

Eslicarbazepine acetate, referred to as ESL) is an oral anti-epileptic drug and a new type of anticonvulsant drug (Na⁺ channel blocker). It reduces the frequency and intensity of epileptic seizures by stabilizing nerve cell membrane potential and inhibiting overexcited sodium channel activity. Compared with traditional carbamazepine, eslicarbazepine is metabolized in the body mainly to form the active metabolite eslicarbazepine (eslicarbazepine), which has better tolerance and pharmacodynamic stability.

Eslicarbazepine is mainly used for the treatment of partial-onset epilepsy (focal-onset seizures), including patients with or without secondary generalized seizures. Suitable for adults and children over 12 years old. It can be used as a single drug or as an adjunctive drug, especially for patients who have poor tolerance or poor control of other anti-epileptic drugs. By inhibiting abnormal neuron discharge, eslicarbazepine can significantly reduce the frequency of epileptic seizures and improve patients' quality of life.

Clinical studies have shown that eslicarbazepine alone or in combination can effectively control partial seizures, and the incidence of side effects is lower than that of traditional drugs. It is convenient for oral administration, has stable blood concentration, and has high patient compliance. Compared with carbamazepine, eslicarbazepine has less hepatic enzyme induction, lower risk of drug interactions, and can reduce the occurrence of central nervous system side effects such as dizziness and drowsiness.

When using eslicarbide, attention should be paid to hematology and liver and kidney function indicators. In particular, patients with abnormal liver function or renal insufficiency should adjust the dose. Common side effects include dizziness, drowsiness, blurred vision, and gastrointestinal upset, which are generally well tolerated. Sudden discontinuation of medication should be avoided while taking the medication to prevent aggravation of epileptic seizures. Doctors will develop an individualized dosage plan based on the patient's weight, seizure type, and combined medication, and conduct regular follow-up visits to evaluate efficacy and safety.

Reference link:https://www.drugs.com